As of August 1999, ImmuLogic Pharmaceutical Corporation ceased operation . The company had operated as a biopharmaceutical company with a primary emphasis on the diagnosis and treatment of allergies and on the immunological treatment of addiction. In March 1999, the Board of Directors of ImmuLogic approved a plan to liquidate and dissolve the company. The Plan was approved by a majority of the stockholders of ImmuLogic in August 1999. The Plan was the end result of the restructuring, which began in 1997 and included the sale of the company's programs to Xenova plc, various sales of assets and IP and the sub-lease of its Waltham, Massachusetts facility, and a reduction in workforce.
